Panoply™ Human SMARCA4 Knockdown Stable Cell Line

Name: Panoply™ Human SMARCA4 Knockdown Stable Cell Line
SKU: CSC-DC014724
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-DC014724

Host Cell : HEK293 (Hela and other cell types are also available) Validation : Real-Time RCR

Inquire for Price

Cell Line Information

Safety and Packaging

Gene Information

Cat. No.	CSC-DC014724
Description	Creative Biogene's Knockdown Cell Lines are target specific shRNA lentivirus transduced cells. The percent knockdown levels range from 75-99% depending on the gene, as evaluated by Real-Time RCR. Cells are rigorously qualified and mycoplasma free.
Target Gene	SMARCA4
Host Cell	HEK293 (Hela and other cell types are also available)
Host Cell Species	Homo sapiens (Human)
Applications	(1) Studying gene functions (2) Studying gene interactions and signaling pathways (3) Target validation and drug discovery (4) Designing diseases models
Size	>1 × 10⁶ cells / vial
Stability	Validated for at least 10 passages
Validation	Real-Time RCR
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Storage	Liquid Nitrogen
Shipping	Dry Ice

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Gene Name	SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 [ Homo sapiens ]
Gene Symbol	SMARCA4
Synonyms	BRG1; SNF2; SWI2; MRD16; RTPS2; BAF190; SNF2L4; SNF2LB; hSNF2b; BAF190A
GeneID	6597
Uni ProtID	A7E2E1
mRNA Refseq	NM_001128844.1
Protein Refseq	NP_001122316.1
Chromosome Location	19p13.2
Function	ATP binding; DNA-dependent ATPase activity; RNA polymerase II regulatory region sequence-specific DNA binding; Tat protein binding; androgen receptor binding; chromatin binding; helicase activity; histone acetyl-lysine binding; p53 binding; protein N-terminus binding; protein binding; transcription coactivator activity; transcription coactivator activity; transcription corepressor activity;
Pathway	Direct p53 effectors, organism-specific biosystem; Glucocorticoid receptor regulatory network, organism-specific biosystem; Integrated Breast Cancer Pathway, organism-specific biosystem; Regulation of Wnt-mediated beta catenin signaling and target gene transcription, organism-specific biosystem; Regulation of retinoblastoma protein, organism-specific biosystem; TNF-alpha/NF-kB Signaling Pathway, organism-specific biosystem;
MIM	603254

Quick Inquiry

Case Study

Q & A

Customer Reviews

The tumor suppressor gene SMARCA4 is a key component of the SWI/SNF chromatin remodeling complex and is frequently inactivated in various cancers, including clear cell renal cell carcinoma (ccRCC). Despite its importance, the role of SMARCA4 in the development and progression of ccRCC and its potential therapeutic targets remain largely unexplored. Here, researchers found that SMARCA4 deficiency is associated with poor prognosis and is observed in some high-grade ccRCC. Through functional analysis, they determined that inhibition of SMARCA4 leads to increased RCC cell proliferation. Further gene expression analysis revealed that SMARCA4-deficient cells exhibit upregulation of the oxidative phosphorylation (OXPHOS) pathway. Furthermore, SMARCA4-deficient RCC cells and xenografts showed greater sensitivity to inhibition of the OXPHOS pathway by the novel small molecule IACS-010759. This sensitivity is attributed to the higher energy demand and sensitivity to energy stress observed in SMARCA4-deficient cells, which are driven by their enhanced biosynthetic needs.

Here, researchers constructed a SMARCA4 knockdown cell line. The results showed enhanced cell proliferation, invasion, and migration in SMARCA4-knockdown ACHN and 786-O cells (Figure 1). In summary, these findings highlight the indispensable role of SMARCA4 in regulating the tumorigenic and metastatic behavior of renal cell carcinoma (RCC) cells, underscoring its potential as a key therapeutic target for clear cell renal cell carcinoma (ccRCC).

Figure 1. SMARCA4 knockdown enhanced the proliferation, invasion, and migration abilities of ACHN and 786-O cells. (Fang, Ru, et al., 2025)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *